by I. Edwards
Novo Nordisk, a Danish pharmaceutical firm, has signed a serious deal value as much as $2 billion for the rights to a brand new weight problems and diabetes drug, the corporate introduced March 24.
The drug, referred to as UBT251, is being developed by United Bio-Know-how (Hengqin) Co., a Chinese language pharmaceutical firm.
Novo Nordisk pays $200 million up entrance, with as much as $1.8 billion in extra funds down the road, The Wall Avenue Journal reported.
The corporate additionally agreed to pay royalties primarily based on future gross sales.
Novo Nordisk now holds the unique rights to develop, manufacture and promote the drug worldwide, besides in mainland China, Hong Kong, Macau and Taiwan.
UBT251 is completely different from Novo Nordisk’s present medicine like Ozempic and Wegovy.
The drug combines GLP-1 and GIP, which decrease urge for food and blood sugar, with glucagon, which helps forestall dangerously low blood sugar ranges.
“The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living with these highly prevalent diseases,” Martin Holst Lange, government vice chairman for growth at Novo Nordisk, instructed The Wall Avenue Journal.
UBT251 is already authorised for early scientific trials in China for adults with kind 2 diabetes, fatty liver illness, power kidney illness and people who are chubby or overweight. Additionally it is authorised for related trials within the U.S.
The deal comes as Novo Nordisk works to broaden its lineup of superior weight-loss remedies.
Though the corporate’s medicine have been in style, trials of a few of its experimental remedies have had combined outcomes.
Buyers are additionally watching intently due to considerations over pricing within the U.S. and rising competitors within the weight problems drug market.
Novo Nordisk’s foremost rival, Eli Lilly, makes the GLP-1/GIP drug tirzepatide, offered as Zepbound and Mounjaro. Eli Lilly can be engaged on a next-generation drug, retatrutide,
Extra info:
Study extra concerning the new drug at Novo Nordisk.
Quotation:
Novo Nordisk to pay $2 billion for brand new weight reduction drug (2025, March 25)
retrieved 26 March 2025
from https://medicalxpress.com/information/2025-03-novo-nordisk-pay-billion-weight.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
